Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia - ARO-DIMER-PA is the first clinical ...

- ARO-DIMER-PA is designed to selectively silence the expression of two genes with a single RNAi molecule using Arrowhead’s proprietary TRiM TM technology - In preclinical studies ARO-DIMER-PA ...

Arrowhead Pharmaceuticals has hit the bullseye with its first successful commercial target, after the US Food and Drug Administration (FDA) approved the company’s small interfering RNA (siRNA) ...

Novartis (NVS) has entered into a licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. (ARWR) for the latter’s ARO-SNCA. ARO-SNCA is Arrowhead’s preclinical stage siRNA therapy ...

Sarepta Therapeutics has shared initial clinical data on two siRNA candidates, delivering an early look at the wisdom of its decision to bet big on Arrowhead Pharmaceuticals’ pipeline.

Novartis is taking another shot at alpha-synuclein as a target for treating Parkinson’s disease via a $200 million upfront licensing deal with Arrowhead Pharmaceuticals. The Swiss pharma plans to use ...

Novartis has agreed to license and develop Arrowhead Pharmaceuticals’ preclinical stage small interfering RNA (siRNA) therapy ARO-SNCA, a potential treatment for Parkinson’s disease and other ...

- ARO-DIMER-PA is the first clinical candidate designed to silence the expression of two genes with a single RNAi molecule - In preclinical studies, ARO-DIMER-PA potently lowered serum PCSK9 and APOC3 ...